XML 44 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Litigation
3 Months Ended
Mar. 31, 2013
Litigation  
Litigation

10.     Litigation

 

In March and April 2013, two lawsuits were filed in the United States District Court for the District of Delaware against the Company, its chief executive officer, its former chief commercial officer, and its chief drug development and medical officer.  The complaints each allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of a purported class of purchasers of the Company’s stock between April 26, 2012 and August 1, 2012.  In general, the complaints allege that the defendants issued materially false or misleading statements concerning the Company’s business and prospects relating to the commercial launch of JAKAFI.  The complaints seek damages in an unspecified amount, equitable relief of an unspecified nature, and costs and expenses of litigation.  The Company believes it has meritorious defenses and intends to vigorously defend itself against these lawsuits.   The Company is unable to estimate the possible loss or range of loss, if any, at this time.